Literature DB >> 12750807

[Guidelines of German urologists on therapy of benign prostate syndrome].

R Berges, K Dreikorn, K Höfner, U Jonas, K U Laval, S Madersbacher, M C Michel, R Muschter, M Oelke, L Pientka, C Tschuschke, U Tunn, H Palmtag, M Goepel, K Schalhhäuser, B Göckeel-Beining, A Heidenreich, H Rübben, K Schalkerhäuser, W Thon, J Thüroff, W Weidner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12750807     DOI： 10.1007/s00120-003-0318-3

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  5 in total

1.  [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study].

Authors:  J Sökeland; J Albrecht
Journal:  Urologe A       Date:  1997-07       Impact factor: 0.639

2.  A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.

Authors:  K F Klippel; D M Hiltl; B Schipp
Journal:  Br J Urol       Date:  1997-09

3.  Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.

Authors:  J C Carraro; J P Raynaud; G Koch; G D Chisholm; F Di Silverio; P Teillac; F C Da Silva; J Cauquil; D K Chopin; F C Hamdy; M Hanus; D Hauri; A Kalinteris; J Marencak; A Perier; P Perrin
Journal:  Prostate       Date:  1996-10       Impact factor: 4.104

4.  Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study.

Authors:  A C Buck; R Cox; R W Rees; L Ebeling; A John
Journal:  Br J Urol       Date:  1990-10

5.  Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

Authors:  R R Berges; J Windeler; H J Trampisch; T Senge
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321
  5 in total
  9 in total

Review 1.  [Surgical and instrumental management of benign prostatic hyperplasia].

Authors:  R Muschter; O Reich
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

2.  [Urology update seminar UroUpdate. Düsseldorf 27th-28th February 2009].

Authors:  U Ayazpoor
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

3.  [Transurethral resection of the prostate and current modifications (bipolar, electrovaporization)].

Authors:  R Muschter; T Bach; M Seitz
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

Review 4.  [Phytotherapy for BPS. Which products can still be prescribed?].

Authors:  S Madersbacher; G Schatzl; C Brössner; K Dreikorn
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

5.  [Benign prostatic syndrome (BPS). Ablative treatments].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; A Bachmann; C Stief
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

Review 6.  [Drug therapy for benign prostatic hyperplasia. Systematic overview].

Authors:  R Berges; K Höfner
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

Review 7.  Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complications.

Authors:  Daniel M Handzel; Sebastian Briesen; Steffen Rausch; Tilman Kälble
Journal:  Dtsch Arztebl Int       Date:  2012-05-25       Impact factor: 5.594

8.  Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners.

Authors:  Takashi Fukagai; Kunitaka Maruyama; Masakazu Nagata; Masashi Morita; Michio Naoe; Hideki Yoshida
Journal:  Int J Urol       Date:  2007-05       Impact factor: 3.369

9.  Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines.

Authors:  Jae-Seung Paick; Soo Woong Kim; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.